-+ 0.00%
-+ 0.00%
-+ 0.00%

*Rocket Pharma: First Patient Dosing in Phase 1 Study of RP-A701 for BAG3-related Dilated Cardiomyopathy Anticipated in Mid-2026 >RCKT

Dow Jones·05/07/2026 20:04:00

Please log in to view news